Bezpečnost sekukinumabu v terapii psoriázy // SOLEN

Dermatológia pre prax 3/2018

Bezpečnost sekukinumabu v terapii psoriázy

The safety of secukinumab in treating psoriasis

Secukinumab shows a highly favourable safety profile, particularly in comparison with standard types of treatment, such as methotrexate use, but also when compared with TNF-α blockers. The use of secukinumab is not accompanied by organ toxicity, serious infections, multiple sclerosis, reactivation of latent tuberculosis or hepatitis B, leukaemia/lymphoma, and non-melanoma skin cancers. The drug has been shown to have therapeutic effect as well as safety and can be accepted as standard in long-term psoriasis treatment.

Keywords: psoriasis, biological therapy, secukinumab, safety